Skip to content

Compare methods

Compare source explanations, strengths, limitations and references for up to four methods.

7 results
Criterion POEM SCORAD EASI
Overview
  • The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.
  • The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.
  • The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA).
Use and interpretation
  • POEM is ideal for longitudinal monitoring in both clinical practice and trials, particularly when frequent assessment is needed (weekly or bi-weekly). It is especially useful for telemedicine visits, home-based monitoring, and populations unable to attend in-person clinician assessments. POEM complements objective measures; in modern trials, POEM and an objective measure (EASI or SCORAD) are often used together. For pure severity grading at a single timepoint, a clinician-rated measure may be preferred, but POEM is superior for tracking change and capturing patient experience.
  • SCORAD is indicated in specialist dermatology settings (secondary and tertiary care) for patients with moderate-to-severe atopic dermatitis. It is essential in clinical trials and for baseline/longitudinal monitoring of systemic therapy. It requires clinician training and is less practical in primary care due to time and expertise demands. SCORAD is preferred over simple extent-only measures because it captures both objective disease burden and subjective impact.
  • EASI is the primary severity measure in clinical trials of atopic dermatitis across all therapeutic classes (topical, systemic, biologic). It is recommended by the US FDA and European Medicines Agency (EMA) as a co-primary or primary endpoint. In clinical practice, EASI is used in specialist dermatology settings to document baseline severity, track treatment response, and justify escalation to systemic therapy. It is less practical in primary care due to examination requirements and clinician training needs.
Strengths
  • Patient-administered; no clinician expertise or training required, enabling use in any setting (primary care, telemedicine, home).
  • Practical and brief; completion takes 2–3 minutes; low respondent burden increases compliance.
  • Validated from age 2 years upward; reliable in both children and adults.
  • Responsive to treatment change; sensitive to clinically meaningful improvement.
  • Captures patient-centered outcomes; frequency of itching and sleep loss align with quality-of-life impact.
  • Suitable for frequent assessment; symptom frequency over past 7 days enables weekly tracking.
  • Strong internal consistency and test-retest reliability in diverse populations.
  • Validated globally with strong inter-rater and test-retest reliability.
  • Combines objective clinical assessment with patient-reported outcomes (pruritus and sleep disruption).
  • Sensitive to change over time; responsive to topical and systemic treatments.
  • Recommended as a primary endpoint in international clinical trials by regulatory agencies.
  • Captures the full spectrum of disease severity from mild to severe.
  • Highly responsive to treatment; sensitivity to change is superior to extent-only measures.
  • Objective assessment reduces observer bias compared to global impression scores.
  • Region-weighted algorithm reflects clinical priorities; head/neck and upper limb involvement weighted higher.
  • Validated across pediatric (age 2+) and adult populations with strong inter-rater and test-retest reliability.
  • Regulatory approval: accepted by FDA and EMA as primary efficacy endpoint in pivotal trials.
  • Clear severity thresholds facilitate communication among clinicians and across studies.
Limitations
  • Subjective recall; patients may not accurately remember symptom frequency over a 7-day period, especially for mild symptoms.
  • Does not capture clinician-observable signs (extent, lichenification, induration); purely symptom-based.
  • Ceiling effects possible in very severe disease; differentiation between 'every day' responses is limited.
  • Culturally sensitive interpretation of terms (e.g., 'oozing') may vary; translations require validation.
  • Sleep loss item may conflate atopic dermatitis with other sleep disruptions (stress, comorbid sleep disorders).
  • Not suitable for very young children (<2 years); parental proxy rating may underestimate infant symptoms.
  • Requires trained clinician administration; not suitable for patient self-assessment or remote monitoring.
  • Time-consuming (10–15 minutes); impractical for high-volume primary care clinics.
  • Subjective extent estimation (percentage body surface area) introduces variability; inter-rater agreement for extent is moderate.
  • VAS components (pruritus, sleep loss) can fluctuate daily, potentially causing score instability.
  • Ceiling effects may limit ability to detect changes in very mild disease.
  • Requires trained clinician administration; not suitable for patient self-assessment or home monitoring.
  • Time-consuming; typically 10–15 minutes, limiting practical use in high-volume clinics.
  • Area estimation introduces variability; inter-rater agreement for percentage affected is moderate, especially for mid-range estimates (20–80%).
  • Weighted regional factors may not apply uniformly across all populations (e.g., different clinical priorities in cosmetically sensitive regions across cultures).
  • Sign intensity assessment (particularly lichenification and induration) can be subjective and training-dependent.
Common pitfalls
  • Using POEM as the sole severity measure in clinical trials; objective assessment (EASI or SCORAD) should always accompany POEM to capture clinician-observable disease extent and sign intensity.
  • Interpreting POEM scores in isolation without understanding the underlying symptoms; a POEM of 8 (mild-moderate) with predominant itching is clinically different from a POEM of 8 with predominant oozing.
  • Assuming POEM is interchangeable with SCORAD or EASI; POEM measures symptom frequency, not sign intensity or body surface area involvement, and does not directly correlate with objective measures.
  • Failing to assess adherence or understanding; patients may misinterpret 'days' (calendar days vs. nights vs. any symptom during the day).
  • Using POEM in infants under 2 years with parental proxy rating without validating the parent's understanding of each symptom.
  • Failing to assess all body regions systematically; clinicians may underestimate disease extent if they do not examine covered areas.
  • Conflating SCORAD with EASI; while similar, EASI does not include subjective components and may not correlate perfectly with quality-of-life impact.
  • Using outdated cutoff thresholds without accounting for population differences; mild/moderate/severe boundaries may vary by trial protocol.
  • Administering without proper training on sign intensity grading; interclinician variability is highest for subjective signs like lichenification.
  • Miscalculating regional weights; clinicians must memorize head/neck=0.1, upper limbs=0.2, trunk=0.2, lower limbs=0.4 or use validated calculators; manual arithmetic errors are common.
  • Assessing only visible lesions; clinicians must examine all four regions, including upper back and scalp, which are often overlooked.
  • Confounding area and intensity; clinicians may incorrectly apply the same severity grade to a large area with mild signs as to a small area with intense signs.
  • Using EASI in settings where it is not feasible (telemedicine, primary care without training) and then comparing results to specialist-administered assessments.
  • Forgetting to divide by 4 within each regional calculation; this error inflates the regional scores and total EASI.
Introduced by
  • Charman CR, Venn AJ, Williams HC
  • European Task Force on Atopic Dermatitis (ETFAD)
  • Hanifin JM, Thurston M
Year
  • 2004
  • 1993
  • 2001